Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Svensson, M; Dahle, DO; Mjen, G; Weihrauch, G; Scharnagl, H; Dobnig, H; März, W; Jardine, A; Fellström, B; Holdaas, H.
Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study.
Nephrol Dial Transplant. 2012; 27(6):2571-2575 Doi: 10.1093/ndt/gfr694 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Dobnig Harald
März Winfried
Scharnagl Hubert
Weihrauch Gisela
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Background. In patients with chronic kidney disease, vascular calcification contributes to increased cardiovascular (CV) morbidity and mortality. CV risk remains high after successful renal transplantation. Osteoprotegerin (OPG) is a glycoprotein, involved in the regulation of the vascular calcification process. Previous studies have shown that elevated OPG is predictive of mortality in high-risk populations. The aim of this study was to investigate the prognostic value of OPG for graft function, CV events and all-cause death, in a large transplant cohort. Methods. OPG was measured at baseline in renal transplant recipients enrolled in the Assessment of Lescol in Renal Transplantation (ALERT) study, a randomized placebo-controlled intervention study comparing fluvastatin and placebo. Patients were followed for 6.7 years with evaluation of pre-specified end points, graft loss, graft function, CV events and death. Results. OPG was analysed in 1889 renal transplant recipients, with a mean value of 4.69 +/- 1.85 pg/L. The number of renal and CV events increased by quartiles of OPG. In the multivariate analysis, OPG in the fourth as compared to first quartile was an independent predictor of graft failure or doubling of serum creatinine [hazard ratio (HR) 2.20 (1.56-3.11), P < 0.001], major CV events [HR 2.40 (1.58-3.64), P < 0.001], cardiac mortality [HR 2.80 (1.32-5.94), P = 0.007] and all-cause mortality [HR 2.31 (1.53-3.49), P < 0.001]. Conclusion. In a large cohort of kidney transplant patients with long-term follow-up, OPG was independently associated with renal events, CV events and mortality.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Anticholesteremic Agents - therapeutic use
Biological Markers - metabolism
Cardiovascular Diseases - diagnosis
Creatinine - blood
Enzyme-Linked Immunosorbent Assay -
Fatty Acids, Monounsaturated - therapeutic use
Female -
Follow-Up Studies -
Graft Rejection - diagnosis
Humans -
Indoles - therapeutic use
Intervention Studies -
Kidney Failure, Chronic - complications
Kidney Transplantation - adverse effects
Male -
Middle Aged -
Osteoprotegerin - metabolism
Prognosis -
Risk Factors -
Survival Rate -
Vascular Calcification - diagnosis

Find related publications in this database (Keywords)
cardiovascular disease
mortality
osteoprotegerin
renal transplantation vascular calcification
© Med Uni Graz Impressum